Advertisement

A Phase 2 Study of Momelotinib, a Potent JAK1 and JAK2 inhibitor, in Patients With Polycythemia Vera or Essential Thrombocythemia

This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100 mg and 200 mg) for the treatment of polycythemia vera and essential thrombocythemia. Ultimately, the study was terminated due to limited efficacy.

 Leuk Res

click me